Soft Mist Inhalers: Lung Deposition Benefits for Respiratory Conditions
By Upperton Pharma Solutions
Biopharma companies are under continued pressure to respond to the global increase in acute respiratory conditions, with the global market for inhalation drug delivery devices expected to reach $20.7bn by 2031, growing at a compound annual growth rate (CAGR) of 4.4%. With direct delivery to target sites, rapid onset of action and a reduced risk of systemic side effects compared to oral therapies, the inhalation market is growing at a phenomenal rate.